@article{2793750eb9df43cd90770490103aea16,
title = "In reply",
author = "Farhad Ravandi and Shouhao Zhou and Nicholas Short",
note = "Funding Information: verse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma,”1 published online March 25, 2021, a grant from the New York University{\textquoteright}s Specialized Program of Research Excellence in Melanoma was omitted from the Funding/Support section. This article has been corrected online. 1. Patrinely JR Jr, Johnson R, Lawless AR, et al. Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma. JAMA Oncol. Published online March 25, 2021. doi:10.1001/ jamaoncol.2021.0051",
year = "2021",
month = may,
doi = "10.1001/jamaoncol.2021.0128",
language = "English (US)",
volume = "7",
pages = "784--785",
journal = "JAMA Oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "5",
}
SDG 3 Good Health and Well-being